Get the Stockscreener App
6.19
1.12%
-0.07
Pre-market:
6.65
0.46
+7.43%
Pulmonx Corp stock is traded at $6.19, with a volume of 99,104.
It is down -1.12% in the last 24 hours and up +0.65% over the past month.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
See More
Previous Close:
$6.26
Open:
$6.3
24h Volume:
99,104
Relative Volume:
0.45
Market Cap:
$244.43M
Revenue:
$68.68M
Net Income/Loss:
$-60.84M
P/E Ratio:
-3.8688
EPS:
-1.6
Net Cash Flow:
$-38.42M
1W Performance:
-9.50%
1M Performance:
+0.65%
6M Performance:
-21.84%
1Y Performance:
-52.42%
1-Day Range:
$6.12
$6.50
1-Week Range:
$6.12
$7.008
52-Week Range:
$5.46
$14.84
Pulmonx Corp Stock (LUNG) Company Profile
Name
Pulmonx Corp
Sector
Industry
Phone
650-364-0400
Address
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
6.19 | 244.43M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-04-24 | Initiated | Lake Street | Buy |
| Feb-23-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-05-23 | Initiated | Craig Hallum | Buy |
| Feb-27-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-03-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-01-21 | Initiated | Citigroup | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Neutral |
| Mar-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-26-20 | Initiated | BofA Securities | Buy |
| Oct-26-20 | Initiated | Canaccord Genuity | Buy |
| Oct-26-20 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-26-20 | Initiated | Stifel | Buy |
| Oct-26-20 | Initiated | Wells Fargo | Equal Weight |
View All
Pulmonx Corp Stock (LUNG) Latest News
Pulmonx director French Glendon E. III sells shares worth $29,625 - MSN
Pulmonx director French Glendon E. III sells shares worth $29,625 By Investing.com - Investing.com Canada
Pulmonx Co. (NASDAQ:LUNG) Shares Bought by Barclays PLC - Defense World
JPMorgan Chase & Co. Buys 25,002 Shares of Pulmonx Co. (NASDAQ:LUNG) - Defense World
Brokerages Set Pulmonx Co. (NASDAQ:LUNG) Price Target at $12.75 - MarketBeat
Geode Capital Management LLC Increases Stock Position in Pulmonx Co. (NASDAQ:LUNG) - Defense World
Barclays PLC Boosts Holdings in Pulmonx Co. (NASDAQ:LUNG) - Defense World
State Street Corp Buys 18,592 Shares of Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Pulmonx Co. (NASDAQ:LUNG) Receives $12.75 Average Price Target from Analysts - MarketBeat
Pulmonx Co. (NASDAQ:LUNG) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Citi downgrades Pulmonx stock to Neutral stock, citing lack of clear catalysts for growth - Investing.com
Pulmonx's (LUNG) "Neutral" Rating Reaffirmed at Citigroup - MarketBeat
Jacobs Levy Equity Management Inc. Sells 188,926 Shares of Pulmonx Co. (NASDAQ:LUNG) - MarketBeat
Pulmonx Co. (NASDAQ:LUNG) Shares Purchased by Fmr LLC - Defense World
Fmr LLC Increases Holdings in Pulmonx Co. (NASDAQ:LUNG) - MarketBeat
Polar Asset Management Partners Inc. Takes Position in Pulmonx Co. (NASDAQ:LUNG) - MarketBeat
Atom Investors LP Trims Stock Position in Pulmonx Co. (NASDAQ:LUNG) - MarketBeat
Pulmonx corp general counsel sells shares worth $34,004 By Investing.com - Investing.com Nigeria
Pulmonx chief commercial officer sells shares worth $27,063 By Investing.com - Investing.com Canada
Pulmonx corp general counsel sells shares worth $34,004 - Investing.com
Pulmonx chief commercial officer sells shares worth $27,063 - Investing.com
Parkman Healthcare Partners LLC Acquires Shares of 206,444 Pulmonx Co. (NASDAQ:LUNG) - MarketBeat
Pulmonx director French sells $132,600 in stock By Investing.com - Investing.com Nigeria
Pulmonx (NASDAQ:LUNG) vs. Fractyl Health (NASDAQ:GUTS) Head-To-Head Review - Defense World
Pulmonx director French sells $132,600 in stock - Investing.com
Millrace Asset Group Inc. Purchases Shares of 167,725 Pulmonx Co. (NASDAQ:LUNG) - MarketBeat
Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect? - Yahoo Finance
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers - Yahoo Finance
Endobronchial Valve System Market Explosive Growth - openPR
FMR LLC Bolsters Stake in Pulmonx Corp - GuruFocus.com
Morgan Stanley's Strategic Reduction in Pulmonx Corp Holdings - GuruFocus.com
Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - Yahoo Finance
Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know - Yahoo Finance
Here's What Analysts Are Forecasting For Pulmonx Corporation (NASDAQ:LUNG) After Its Third-Quarter Results - Yahoo Finance UK
Pulmonx Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Pulmonx Corporation (NASDAQ:LUNG) Q3 2024 Earnings Call Transcript - Insider Monkey
Pulmonx Corp (LUNG) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Earnings call: Pulmonx reports solid growth and strategic advances in Q3 - Investing.com UK
Pulmonx Corp (LUNG) Q3 2024 Earnings: Revenue Hits $20.4M, EPS a - GuruFocus.com
Pulmonx Corp (LUNG) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... - Yahoo Finance UK
Pulmonx Corp (LUNG) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... By GuruFocus - Investing.com Canada
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates - MSN
Pulmonx earnings beat by $0.81, revenue topped estimates - Investing.com
Pulmonx Reports Third Quarter 2024 Financial Results - Yahoo Finance
Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
nVerses Capital LLC Buys Shares of 3,100 Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx (LUNG) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Pulmonx director sells $130,399 in common stock By Investing.com - Investing.com South Africa
Pulmonx director sells $130,399 in common stock - Investing.com India
Pulmonx Corp Stock (LUNG) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):